391056130 = Stuart Monk|||

Markets have started the day off with solid gains, broad-based among virtually all sectors. The passage of major US tax cuts pushed against some macroeconomic headwinds, including a US Q3 GDP estimate that came in under expectations. The US job market also posted a poor month, but tax cut optimism reigned supreme.

Today’s Top Performer comes from the pharmaceutical sector. As the market remains near all-time highs, investors remain hungry for stocks that aren’t already fully valued at their long-term earning potential. Pharmaceutical companies continue to generate substantial same-day price movement—a  single patent or clinical trial announcement can create or end whole product lines.

With the right real-time news analytics tool—like News Quantified—investors can ride these same-day price swings to truly dramatic gains.

Aeterna Zentaris (AEZS): jumps on news of FDA approval for innovative new treatment.

Aeterna Zentaris is a drug development and commercialization company. This morning, they announced that the FDA has approved their drug Macrilen, to be used in the diagnosis of Adult Growth Hormone Deficiency. AEZS estimates that around 60,000 AGHD tests are currently issued to patients in the US, Canada, and Europe every year.

Macrilen is orally ingested, and aids in the detection of growth hormone deficiencies in subsequent blood samples. It is expected to allow for the use of a quick draw of blood. The current technology requires an hours-long blood drawing session, an immense cost for patient and endocrinologist.

With such a clear-cut advantage over current approaches, Macrilen is expected to command substantial market share. Investors bought the stock on heavy volume after the announcement, driving the stock to gains around 45% at the time of this writing. The stock had shot up to gains near 100% before consolidating at its current price level.

Diverse Plays, Great Profits: All in a single news day.

Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!

We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.

Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock

A powerful news analytics platform like News Quantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.

How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like News Quantified?  Let us know in the comments below.